Glaxosmithkline | GSK - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 1000K 2026-06
Amgen USD 4.78B 1.12B 2026-03
AstraZeneca USD 12.22B 4.04B 2026-06
Aurora Cannabis CAD 48.04M 81.94M 2026-03
Bausch Health Companies USD 2.08B 41M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Canopy Growth CAD 98.72M 11.51M 2026-03
Corcept Therapeutics USD 214.85M 343K 2026-06
Drreddys Laboratories INR 74.33B 1.4B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
GlaxoSmithKline GBP 5.8B 468M 2026-06
Glaxosmithkline GBP 5.34B 3.83B 2026-03
J&J USD 17.83B 388M 2026-06
Merck USD 18.17B 8.01B 2026-03
Novartis USD 10.2B 912M 2026-06
Pacira USD 172.75M 20.93M 2026-03
Perrigo USD 935.6M 89.6M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Phibro Animal Health USD 361.83M 29.47M 2026-03
Prestige Brands USD 206.12M 5.17M 2026-03
Roche Holding CHF 18.9B 2.12B 2026-06
Sanofi EUR 9.92B 607M 2026-06
Supernus Pharmaceuticals USD 1.08B 879.06M 2026-03
Takeda JPY 1.02T 89.68B 2026-06
Teva Pharmaceutical Industries USD 3.92B 691M 2026-06
Zoetis USD 3.23B 1.68B 2026-03